Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL561595 | 0.98 | EPHX1 (0.39) | EPHX1MMP1MMP9MMP12SMN1; SMN2 | |
| SCHEMBL525096 | 0.95 | EPHX1 (0.35) | EPHX1MMP1MMP9MMP12SMN1; SMN2 | |
| SCHEMBL20469204 | 0.91 | CCNE1 (0.38) | CCNE1CDK2GSK3BFAAHMGLL | |
| SCHEMBL20629735 | 0.88 | SMN1; SMN2 (0.37) | EPHX1SMN1; SMN2CYP2C19TSHRCYP3A4 | |
| SCHEMBL19447858 | 0.86 | CCNE1 (0.35) | EPHX1SMN1; SMN2CYP2C19TSHRCYP3A4 | |
| SCHEMBL1300093 | 0.85 | CCNE1 (0.34) | EPHX1MMP1MMP9MMP12CCNE1 | |
| SCHEMBL27365535 | 0.85 | CCNE1 (0.34) | EPHX1MMP1MMP9MMP12CCNE1 | |
| SCHEMBL31736019 | 0.85 | CCNE1 (0.34) | EPHX1MMP1MMP9MMP12CCNE1 | |
| SCHEMBL1300090 | 0.85 | CCNE1 (0.34) | EPHX1MMP1MMP9MMP12CCNE1 | |
| SCHEMBL27385617 | 0.85 | CCNE1 (0.34) | EPHX1MMP1MMP9MMP12CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3427738-B1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMA (US) | 2021-12-01 | — | — | EP | disclosed |
| EP-3427738-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | Vertex Pharmaceuticals Incorporated (US) | 2019-01-16 | — | — | EP | disclosed |
| EP-3141252-B1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMA (US) | 2018-07-25 | — | — | EP | disclosed |
| EP-3141252-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | Vertex Pharmaceuticals Inc. (US) | 2017-03-15 | — | — | EP | disclosed |
| US-8338469-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2012-12-25 | — | — | US | disclosed |
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME CORP. | 2012-02-16 | — | — | US | disclosed |
| US-20110257077-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2011-10-20 | — | — | US | disclosed |
| US-7951823-B2 | Compounds and compositions as channel activating protease inhibitors | IRM LLC (BM) | 2011-05-31 | — | — | US | disclosed |
| EP-2027143-A2 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2009-02-25 | — | — | EP | disclosed |
| WO-2007137080-A2 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | IRM LLC (BM) | 2007-11-29 | — | — | WO | disclosed |
| US-20070275906-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | IRM LLC (BM) | 2007-11-29 | — | — | US | disclosed |
| WO-2004022554-A1 | QUINAZOLINONE DERIVATIVES | CELLTECH R & D LIMITED (GB) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257077-A1 | COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS | PRSS1, PRSS8, PRSS2 | EPHX1 1875/4885MMP1 127/4885MMP9 146/4885 |
| US-20120040975-A1 | BRIDGED BICYCLIC HETEROCYCLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, BDKRB2, GLP1R | EPHX1 1358/4885MMP1 4637/4885MMP9 3060/4885 |
| US-20070275906-A1 | Compounds and Compositions as Channel Activating Protease Inhibitors | PRSS1, PRSS8, PRSS2 | EPHX1 1875/4885MMP1 127/4885MMP9 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.